EBRD supports Poland's Polpharma
Photo by Piotr Swat / Shutterstock.com
The European Bank for Reconstruction and Development (EBRD) is providing Polish largest pharmaceuticals producer Polpharma with a PLN 200 million (EUR 45 million) loan for general and corporate purposes including in-house R&D activities, green investments and ESG strategy, it said in a statement.
Investment in new technologies will unlock the development of new substances and products in currently unavailable niches.
The EBRD loan will also be used for the implementation of a "Go green" modernization programme aimed at minimizing the environmental and climate impact of the company's operations.
Policymakers Cut Central Bank Base Rate by 50 bp to 7.75%
Bulgaria's Household Income, Spending Rise 20% in 2023
Spar Magyarország Revenue Climbs Close to 16% in 2023
Hungary Launches HUF 15 bln Tourism Sector Support Program
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
